Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Memorial Sloan Kettering Cancer Center · The University of Texas MD Anderson Cancer Center
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
628
total citations
- FWCI
- 7.03
- Percentile
- 100%
- References
- 85
Citations per year
Authors
10- MDMatthew D. Hellmann
Memorial Sloan Kettering Cancer Center
- JEJamie E. Chaft
Memorial Sloan Kettering Cancer Center
- WNWilliam N. William
The University of Texas MD Anderson Cancer Center
- VWValerie W. Rusch
Memorial Sloan Kettering Cancer Center
- KMKatherine M.W. Pisters
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Pathological
- Medicine
- Surrogate endpoint
- Clinical endpoint
- Neoadjuvant therapy
- Oncology
- Chemotherapy
- Clinical trial
UN Sustainable Development Goals
- Industry, innovation and infrastructure
No related works found for this paper.